S6.14.3 – Louise and Roger React to Empowered SLD Patient Advocates
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
October 9, 2025
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
Louise Campbell drives this conversation, which focuses largely on issues related to MASH patient management. Her general point is that we need to take a more holistic look at MASH patient management, including self-management. Jörn Schattenberg and Roger Green share comments and questions.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval on MAH therapy in the U.S. This conversation covers the larger, downstream changes we will see in how MASLD and MASH are treated in the U.S.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers how the healthcare system will manage the tsunami of new patients resulting from increases in disease education and publicity.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers pharmacotherapy choices and the benefits this decision offers for patients.
Four leading US KOLs join Roger Green to discuss how the recent FDA approval of semaglutide in MASH will lead to dramatic changes in MASLD care in the US.
Physicians Who Run Multi-Metabolic Clinics in the US and Spain Join Louise Campbell To Discuss Their Clinics (Part I)
This episode focuses on “multi-metabolic medicine,” including a roundtable whose guests run multi-metabolic practices in the US and Spain and an interview with Dr. Emily Andaya, an advocate for including the liver in the American Heart Associations’s CKM initiative.
LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos join Roger Green to discuss the launch of America’s first virtual hepatology clinic and the reason they created it.
Jörn Schattenberg, Louise Campbell and Roger Green discuss how future NITs can help prescribers decide where to focus therapy, LiverRight executives describe the first virtual hepatology clinic and simple large-scale data analysis identifies high-risk liver patients unaware of their risks.